Description
API intends to perform the end to end manufacturing of antimicrobial drug products as a demonstration of domestic medicine manufacturing capabilities.
Amendment chain · 1 entry
Each notch is one published row for this agreement: #0 is the original (placed at its start date) and each later notch is an amendment (placed at its amendment date). The height is the agreement's total value as of that row — the source column is cumulative, not a change amount — so the line reads as the commitment over time and the right-most notch is the current commitment shown in the header.
- #02026-01-13$21,928,275
| Row | Date | Total value as of row | Change vs previous | Description on this row |
|---|---|---|---|---|
| #0 original | 2026-01-13(start date) | $21,928,275 | — | API intends to perform the end to end manufacturing of antimicrobial drug products as a demonstration of domes… |
Related records · 8
Records are related by an explicit link in the data, stated for each group below — never by text similarity. Values are each agreement's current commitment (latest amendment).
Other current agreements for the same recipient (business number 723985719)
| Ref | Department · program | Current value | FY |
|---|---|---|---|
| GC-WD-DEO-2024-2025-Q2-8 | Prairies Economic Development Canada | Développement économique Canada pour les Prairies · Regional Economic Growth through Innovation | $30,000 | FY2025 |
| 044-2025-2026-Q4-00067 | Prairies Economic Development Canada | Développement économique Canada pour les Prairies · Regional Economic Growth through Innovation | $130,514,000 | FY2023 |
| GC-WD-DEO-2022-2023-Q4-105 | Prairies Economic Development Canada | Développement économique Canada pour les Prairies · Regional Economic Growth through Innovation | $80,514,000 | FY2023 |
Other recipients funded under "Life Sciences Fund Contributions" by Innovation, Science and Economic Development Canada | Innovation, Sciences et Développement économique Canada (most recent first)
| Ref | Recipient | Fiscal year | Current value | FY |
|---|---|---|---|---|
| 033-2025-2026-Q4-515888 | STEMCELL Technologies Canada Inc. | FY2026 | $2,829,286 | FY2026 |
| 033-2025-2026-Q4-515732 | Avivo Biomedical Inc | FY2026 | $10,994,000 | FY2026 |
| 033-2025-2026-Q4-515743 | Northern RNA Inc. | FY2026 | $6,037,700 | FY2026 |
| 033-2025-2026-Q4-515746 | Avivo Biomedical Inc | FY2026 | $10,994,000 | FY2026 |
| 033-2025-2026-Q4-515741 | Qidni Labs Inc. | FY2026 | $12,500,000 | FY2026 |
Cite as: Glassbox record view · Federal grants & contributions · 033-2025-2026-Q4-515742 · retrieved 2026-11-12.